Hospital  Internal MedicineⅢ 

Research Interests 【 display / non-display

  • 血液内科学

Graduating School 【 display / non-display

  • 2003.04

    Akita University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display


    Akita University  Graduate School, Division of Medicine  Doctor's Course  Completed

Campus Career 【 display / non-display

  • 2024.04

    Akita University   Hospital   Internal MedicineⅢ   Lecturer  

  • 2022.04

    Akita University   Hospital   Internal MedicineⅢ   Assistant Professor  

  • 2020.10

    Akita University   Hospital   Central Laboratory Division   Assistant Professor  

Research Areas 【 display / non-display

  • Life Science / Hematology and medical oncology  / 血液腫瘍内科

Qualification acquired 【 display / non-display

  • Doctor


Thesis for a degree 【 display / non-display

  • Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide

    小林 敬宏 

    Therapeutic Drug Monitoring    2018.09  [Refereed]

    Domestic Co-author

Research Achievements 【 display / non-display

    ◆Other【 display / non-display

  • Postmortem diagnosis of intravascular large B-cell lymphoma after atraumatic splenic rupture due to splenic infiltration

    KUROKI Wataru, KOBAYASHI Takahiro, UMAKOSHI Michinobu, KITADATE Akihiro, IMAIZUMI Chihiro, SAITO Masaya, KOBAYASHI Isuzu, FUJISHIMA Masumi, FUJISHIMA Naohito, YOSHIOKA Tomoko, GOTO Akiteru, TAKAHASHI Naoto

    Rinsho Ketsueki ( The Japanese Society of Hematology )  63 ( 6 ) 523 - 529   2022

    <p>Atraumatic splenic rupture (ASR) is a rare but fatal complication of malignant lymphoma. However, only one case of intravascular large B-cell lymphoma (IVLBCL)-related ASR (IVLBCL-ASR) has previously been reported, and the mechanism of IVLBCL-ASR is unknown. We present the case of a 78-year-old man who died unexpectedly and was diagnosed with IVLBCL-ASR pathologically by autopsy. A massive intraperitoneal hemorrhage and four lacerations on the splenic surface were discovered during the autopsy. CD20-positive lymphoma cells that infiltrated into small vessels were highly concentrated in the center of the spleen and were only slightly distributed in the lacerations on the splenic surface. Therefore, increased intrasplenic pressure due to lymphoma cell proliferation was identified as the cause of ASR. The patient had undergone <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) for tongue cancer evaluation 3 months earlier, and positive uptake was found in the right adrenal gland, where lymphoma cell infiltration was confirmed by the autopsy. Our findings suggest that clinicians should be aware that the advanced stage of IVLBCL can cause fatal ASR via increased intrasplenic pressure. Therefore, early diagnosis and early treatment intervention are desirable to prevent the onset of IVLBCL-ASR, and <sup>18</sup>F-FDG PET/CT is useful for the early diagnosis of IVLBCL.</p>

    DOI PubMed CiNii Research

  • Durable remission attained with rituximab therapy in a patient with acquired von Willebrand syndrome associated with CD20-positive lymphoproliferative disorder


    Rinsho Ketsueki ( The Japanese Society of Hematology )  59 ( 4 ) 420 - 425   2018

    <p>A 61-year-old female with no history of bleeding was admitted to our hospital owing to persistent bleeding after the left knee joint injection and activated partial thromboplastin time prolongation. Subsequent coagulation tests revealed a critically declined level of the von Willebrand factor (VWF) antigen (<10%) and activity (<10%) measurement besides a significantly declined factor VIII activity (4%). Despite diagnosing her with acquired von Willebrand syndrome (AvWS) and managing her bleeding with desmopressin acetate hydrate (DDAVP), we could not precisely make a definitive diagnosis the underlying disorder. More than 15 months after the onset of AvWS, CD20-positive atypical lymphocytes appeared in the peripheral blood and bone marrow without systemic lymphadenopathy. We initiated rituximab monotherapy eight times a week for CD20-positive lymphoproliferative disorders. The treatment not only caused the disappearance of the clonal expansion of CD20-positive atypical lymphocytes in both peripheral blood and bone marrow but also exhibited the clinical remission of AvWS. In addition, the maintenance therapy with rituximab every 3 months resulted in the durable remission of over 5 years. AvWS is a rare bleeding disorder, similar to von Willebrand disease, which arises from various underlying diseases. Our experience with this case highlights that rituximab proved to be one of the effective and well-tolerated treatment options for AvWS associated with CD20-positive B-cell lymphoproliferative disorders.</p>


Grant-in-Aid for Scientific Research 【 display / non-display

  • Grant-in-Aid for Early-Career Scientists

    Project Year: 2020.04  -  2023.03